Aixin Life International Inc AIXN

$0.26 +0.01 (3.59%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
P/E (trailing)
—
P/E (forward)
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
200
Avg volume
708
Day's range
$0.26 – $0.26
Shares out
—
Stochastic %K
13%
Beta
—
Analysts
—
Price target
—

Price

Company profile

AiXin Life International, Inc. develops, manufactures, markets, and sells healthcare, nutritional products, and wellness supplements in the People's Republic of China. It operates through Direct Sales, Pharmacy, Hotel, and Manufacture and Sale segments. The company provides herbs, greens, and traditional Chinese remedies; and functional products, such as weight management tools, probiotics, and foods and drinks; and...

Show more

AiXin Life International, Inc. develops, manufactures, markets, and sells healthcare, nutritional products, and wellness supplements in the People's Republic of China. It operates through Direct Sales, Pharmacy, Hotel, and Manufacture and Sale segments. The company provides herbs, greens, and traditional Chinese remedies; and functional products, such as weight management tools, probiotics, and foods and drinks; and rhino king, colostrum powder derived from goat's milk, tong li ke, gammaoling granules, amoxicillin capsules, loratadine tablets, and fuyang granules. It also engages in hotel business. The company provides products manufactured by the company and purchased from third parties, as well as marketing and distribution services to other manufacturers and suppliers of healthcare products. It sells its products through company-owned offices open to clients, pharmacies, direct marketing, e-commerce, exhibition events, conferences, and person-to-person marketing. AiXin Life International, Inc. is based in Chengdu, China.

Industry
Food Distribution
Sector
Consumer Defensive
Phone
86 31 3673 2526
Website
https://www.aixinjituan.com
Address
Hongxing Intl. Business Bldg 2, 14th Floor No. 69 Qingyun South Avenue Jinjiang District, Chengdu, China

Latest news

No headlines yet.